The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Enforcement Against Injectable Colchicine

FDA Enforcement Against Injectable Colchicine

May 1, 2008 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food and Drug Administration (FDA) has ordered companies to stop marketing unapproved drug products that contain colchicines in an injectable dosage form.

You Might Also Like
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • Generic Colchicine Approved for Gout Prophylaxis
Explore This Issue
May 2008
Also By This Author
  • Data-Driven, Optimal Patient Care and Clinical Research

This action was taken because products containing colchicine for intravenous use have been marketed without approval. The FDA is making an effort to ensure that all drugs marketed in the United States have the required FDA approval and are safe, effective, of good quality, and appropriately labeled.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Colchicine is most commonly used for the treatment of gout. Colchicine for injection has been available in the United States since the 1950s and is administered intravenously for the treatment of acute gout attack.

There is an increased likelihood of colchicine toxicity when the drug is administered intravenously. In addition, serious safety concerns associated with the use of intravenous colchicines drugs have caused reports to be made to the FDA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA states that, “among the commonly reported events were neutropenia (low number of white blood cells), acute renal (kidney) failure, thrombocytopenia (low number of platelets), congestive heart failure, and pancytopenia (low number of all types of blood cells). Many of these adverse events are caused by colchicine toxicity, which can have serious and potentially fatal consequences.”

This action by the FDA does not affect colchicine tablets. For additional information, visit the FDA Web site at www.fda.gov or contact Antanya Chung, CCP, CPC, at (404) 633-3777.

Filed Under: Drug Updates, From the College, Safety Tagged With: Colchicine, colchicines, Drugs, FDA, InjectionIssue: May 2008

You Might Also Like:
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium
  • Generic Colchicine Approved for Gout Prophylaxis
  • Colchicine Effective for Acute Pericarditis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.